Phase 2 Study of Novel SEQUEnced Immunotherapy (Pembrolizumab) With Anti-angiogenesis and Chemotherapy in Advanced Gastric and gastroesophageaL Junction (GEJ) Adenocarcinoma
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Paclitaxel (Primary) ; Pembrolizumab (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms SEQUEL
- 30 Nov 2023 Planned End Date changed from 1 Jun 2024 to 10 Dec 2025.
- 30 Nov 2023 Planned primary completion date changed from 1 Nov 2023 to 11 Jun 2025.
- 06 Nov 2023 Planned primary completion date changed from 1 Oct 2023 to 1 Nov 2023.